Contact
searchSearch
HMP Global
Login

Oncology

Featured

Lukas Delasos, DO; Lauren Chiec, MD, Afshin Dowlati, MD
Videos
Round 3: Frontline Therapy Across Age and Fitness Levels
10/28/2026
Afshin Dowlati, MD; Lukas Delasos, DO; Lauren Chiec, MD
In the final round, panelists consider frontline treatment selection for an older, functionally independent patient, weighing toxicity profiles, administration approaches, supportive care, and dose modifications against treatment goals and...
In the final round, panelists consider frontline treatment selection for an older, functionally independent patient, weighing toxicity profiles, administration approaches, supportive care, and dose modifications against treatment goals and...
In the final round, panelists...
10/28/2026
Oncology
Lukas Delasos, DO; Lauren Chiec, MD, Afshin Dowlati, MD
Videos
Round 2: Frontline Therapy for Patients With CNS Disease and Other High-Risk Features
10/28/2026
Afshin Dowlati, MD; Lukas Delasos, DO; Lauren Chiec, MD
The discussion turns to a patient with baseline CNS metastases and a TP53 co-mutation. Panelists explore CNS efficacy, differences in trial assessment methods, and how high-risk disease characteristics influence treatment selection.
The discussion turns to a patient with baseline CNS metastases and a TP53 co-mutation. Panelists explore CNS efficacy, differences in trial assessment methods, and how high-risk disease characteristics influence treatment selection.
The discussion turns to a...
10/28/2026
Oncology
Lukas Delasos, DO; Lauren Chiec, MD, Afshin Dowlati, MD
Videos
Round 1: Frontline Therapy for the Newly Diagnosed Patient
10/28/2026
Afshin Dowlati, MD; Lukas Delasos, DO; Lauren Chiec, MD
The debate begins with a newly diagnosed patient with metastatic EGFR-mutated NSCLC. Panelists examine survival outcomes, durability of disease control, and mechanisms of acquired resistance, including implications for future treatment...
The debate begins with a newly diagnosed patient with metastatic EGFR-mutated NSCLC. Panelists examine survival outcomes, durability of disease control, and mechanisms of acquired resistance, including implications for future treatment...
The debate begins with a newly...
10/28/2026
Oncology
Lukas Delasos, DO; Lauren Chiec, MD, Afshin Dowlati, MD
Videos
Frontline Treatment Selection in EGFR-Mutated NSCLC: Amivantamab-Based vs Osimertinib-Based Therapy
10/28/2026
Afshin Dowlati, MD; Lukas Delasos, DO; Lauren Chiec, MD
Thoracic oncology experts debate frontline treatment selection for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), examining clinical evidence for amivantamab + lazertinib versus osimertinib + platinum/pemetrexed....
Thoracic oncology experts debate frontline treatment selection for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), examining clinical evidence for amivantamab + lazertinib versus osimertinib + platinum/pemetrexed....
Thoracic oncology experts debate...
10/28/2026
Oncology
News
Real-World Study Demonstrates Clinical Activity of Lurbinectedin in Previously Treated Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz...
10/28/2026
Oncology
News
NETSARC+ Study Identifies Tumor Location and Size as Prognostic Factors in Patients With Desmoid Tumors
10/28/2026
Emily Estrada
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+...
10/28/2026
Oncology
News
G-CSF Prophylaxis Reduces Incidence of Febrile Neutropenia Without Compromising Chemoimmunotherapy Outcomes in Patients With Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter,...
10/28/2026
Oncology
News
Tambotatug Pelitecan Significantly Improves Overall Survival in Patients With Relapsed Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3...
10/28/2026
Oncology
News
Oral Hypomethylating Agents Show Comparable Hematologic Toxicity to Intravenous Therapy in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia
10/28/2026
Emily Estrada
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter...
10/28/2026
Oncology
News
Phase 3 Results Support Regulatory Submission of Oral Azacitidine Plus Cedazuridine in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
10/28/2026
Emily Estrada
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND...
10/28/2026
Oncology
News
Varegacestat Demonstrates Promising Antitumor Activity in Patients With Progressive Desmoid Tumors
10/28/2026
Emily Estrada
Results from the phase 2 RINGSIDE trial demonstrated sustained antitumor activity with varegacestat in patients with progressive desmoid tumors, with once daily dosing producing greater tumor volume reductions and higher response rates than...
Results from the phase 2 RINGSIDE trial demonstrated sustained antitumor activity with varegacestat in patients with progressive desmoid tumors, with once daily dosing producing greater tumor volume reductions and higher response rates than...
Results from the phase 2...
10/28/2026
Oncology

Videos

Lukas Delasos, DO; Lauren Chiec, MD, Afshin Dowlati, MD
Videos
Round 3: Frontline Therapy Across Age and Fitness Levels
10/28/2026
Afshin Dowlati, MD; Lukas Delasos, DO; Lauren Chiec, MD
In the final round, panelists consider frontline treatment selection for an older, functionally independent patient, weighing toxicity profiles, administration approaches, supportive care, and dose modifications against treatment goals and...
In the final round, panelists consider frontline treatment selection for an older, functionally independent patient, weighing toxicity profiles, administration approaches, supportive care, and dose modifications against treatment goals and...
In the final round, panelists...
10/28/2026
Oncology
Lukas Delasos, DO; Lauren Chiec, MD, Afshin Dowlati, MD
Videos
Round 2: Frontline Therapy for Patients With CNS Disease and Other High-Risk Features
10/28/2026
Afshin Dowlati, MD; Lukas Delasos, DO; Lauren Chiec, MD
The discussion turns to a patient with baseline CNS metastases and a TP53 co-mutation. Panelists explore CNS efficacy, differences in trial assessment methods, and how high-risk disease characteristics influence treatment selection.
The discussion turns to a patient with baseline CNS metastases and a TP53 co-mutation. Panelists explore CNS efficacy, differences in trial assessment methods, and how high-risk disease characteristics influence treatment selection.
The discussion turns to a...
10/28/2026
Oncology
Lukas Delasos, DO; Lauren Chiec, MD, Afshin Dowlati, MD
Videos
Round 1: Frontline Therapy for the Newly Diagnosed Patient
10/28/2026
Afshin Dowlati, MD; Lukas Delasos, DO; Lauren Chiec, MD
The debate begins with a newly diagnosed patient with metastatic EGFR-mutated NSCLC. Panelists examine survival outcomes, durability of disease control, and mechanisms of acquired resistance, including implications for future treatment...
The debate begins with a newly diagnosed patient with metastatic EGFR-mutated NSCLC. Panelists examine survival outcomes, durability of disease control, and mechanisms of acquired resistance, including implications for future treatment...
The debate begins with a newly...
10/28/2026
Oncology
Lukas Delasos, DO; Lauren Chiec, MD, Afshin Dowlati, MD
Videos
Frontline Treatment Selection in EGFR-Mutated NSCLC: Amivantamab-Based vs Osimertinib-Based Therapy
10/28/2026
Afshin Dowlati, MD; Lukas Delasos, DO; Lauren Chiec, MD
Thoracic oncology experts debate frontline treatment selection for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), examining clinical evidence for amivantamab + lazertinib versus osimertinib + platinum/pemetrexed....
Thoracic oncology experts debate frontline treatment selection for patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC), examining clinical evidence for amivantamab + lazertinib versus osimertinib + platinum/pemetrexed....
Thoracic oncology experts debate...
10/28/2026
Oncology
DLL3 Debate R3
Videos
Round 3: What Is Needed to Establish DLL3 as a Clinically Actionable Biomarker?
10/27/2026
Jonathan Strosberg, MD; Nitya Raj, MD; Anja Roden, MD
In the final round, the discussion shifts from opposing positions to the path forward. Faculty explore the clinical evidence, assay and scoring standards, specimen requirements, reporting practices, and pathology–oncology workflows that would...
In the final round, the discussion shifts from opposing positions to the path forward. Faculty explore the clinical evidence, assay and scoring standards, specimen requirements, reporting practices, and pathology–oncology workflows that would...
In the final round, the...
10/27/2026
Oncology
DLL3 Debate R2
Videos
Round 2: If DLL3 Becomes Actionable in NEC, Who Should Be Tested and When?
10/27/2026
Jonathan Strosberg, MD; Nitya Raj, MD; Anja Roden, MD
As DLL3-directed therapies move into earlier stages of clinical development, questions around testing strategy and timing are becoming increasingly relevant. In Round 2, faculty weigh selective versus broader, earlier DLL3 characterization,...
As DLL3-directed therapies move into earlier stages of clinical development, questions around testing strategy and timing are becoming increasingly relevant. In Round 2, faculty weigh selective versus broader, earlier DLL3 characterization,...
As DLL3-directed therapies move...
10/27/2026
Oncology
DLL3 Debate R1
Videos
Round 1: Is DLL3 a Clinically Actionable Predictive Biomarker in NEC?
10/27/2026
Jonathan Strosberg, MD; Nitya Raj, MD; Anja Roden, MD
Early clinical data suggest a potential relationship between DLL3 expression and response to DLL3-directed therapies, but predictive utility has not yet been established. In Round 1, faculty examine what current clinical evidence does—and...
Early clinical data suggest a potential relationship between DLL3 expression and response to DLL3-directed therapies, but predictive utility has not yet been established. In Round 1, faculty examine what current clinical evidence does—and...
Early clinical data suggest a...
10/27/2026
Oncology
DLL3 Debate Introduction
Videos
DLL3 in Neuroendocrine Malignancies: From Expression Marker to Predictive Biomarker?
10/27/2026
Jonathan Strosberg, MD; Nitya Raj, MD; Anja Roden, MD
DLL3 is an established therapeutic target in small-cell lung cancer and an emerging area of investigation across other neuroendocrine carcinomas. In this 3-round debate, experts in medical oncology and pathology examine the evolving evidence...
DLL3 is an established therapeutic target in small-cell lung cancer and an emerging area of investigation across other neuroendocrine carcinomas. In this 3-round debate, experts in medical oncology and pathology examine the evolving evidence...
DLL3 is an established...
10/27/2026
Oncology
Brian Slomovitz, MD
Videos
KEYNOTE-C93 Demonstrates Superior PFS With Pembrolizumab Monotherapy in dMMR Endometrial Cancer
10/26/2026
Brian M. Slomovitz, MD
Brian Slomovitz, MD, discusses results from the phase 3 KEYNOTE-C93 trial evaluating first-line pembrolizumab monotherapy versus carboplatin plus paclitaxel in advanced or recurrent mismatch repair–deficient endometrial cancer, highlighting...
Brian Slomovitz, MD, discusses results from the phase 3 KEYNOTE-C93 trial evaluating first-line pembrolizumab monotherapy versus carboplatin plus paclitaxel in advanced or recurrent mismatch repair–deficient endometrial cancer, highlighting...
Brian Slomovitz, MD, discusses...
10/26/2026
Oncology
Ferdinandos Skoulidis, MD, PhD
Videos
KRAScendo-1: Divarasib Significantly Improves Survival Over Sotorasib or Adagrasib in KRAS G12C-Mutated Non-Small Cell Lung Cancer
10/25/2026
Ferdinandos Skoulidis, MD, PhD
Ferdinandos Skoulidis, MD, PhD, discusses results from the phase 3 KRAScendo-1 trial demonstrating that divarasib significantly improved survival and response compared with sotorasib or adagrasib in previously treated patients with locally...
Ferdinandos Skoulidis, MD, PhD, discusses results from the phase 3 KRAScendo-1 trial demonstrating that divarasib significantly improved survival and response compared with sotorasib or adagrasib in previously treated patients with locally...
Ferdinandos Skoulidis, MD, PhD,...
10/25/2026
Oncology

Insights From the ASCO Annual Meeting

News
First-in-Class Hepcidin Inhibitor DISC-0974 Demonstrates Activity in Myelofibrosis-Associated Anemia
07/09/2026
Stephanie Holland
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase 2 RALLY-MF trial demonstrated that DISC-0974 produced meaningful hematologic responses and improved fatigue in patients with myelofibrosis-associated anemia, supporting hepcidin inhibition as a potential...
Results from the ongoing, phase...
07/09/2026
Oncology
News
Imetelstat Maintains Overall Survival Advantage Over Best Available Therapy in JAK Inhibitor–Relapsed or Refractory Myelofibrosis
07/09/2026
Stephanie Holland
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc analysis demonstrated that imetelstat continued to improve overall survival compared with best available therapy in patients with JAK inhibitor relapsed or refractory myelofibrosis, despite substantial changes...
Updated results from a post hoc...
07/09/2026
Oncology
Ramaswamy Govindan, MD
Videos
Adjuvant Erlotinib Following Complete Resection of EGFR-Mutant Non-Small Cell Lung Cancer Improves Disease Free Survival But Not Overall Survival
06/29/2026
Ramaswamy Govindan, MD
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD, discusses results from the ALCHEMIST trial evaluating adjuvant erlotinib in resected EGFR-mutant non–small cell lung cancer and the potential for ongoing biomarker studies to identify patients most likely to benefit...
Ramaswamy Govindan, MD,...
06/29/2026
Oncology
Erika Hamilton, MD
Videos
Tucatinib Demonstrates Consistent Benefit Across First-Line HER2-Positive Metastatic Breast Cancer Populations
06/26/2026
Erika Hamilton, MD
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses updated results from the HER2CLIMB-05 trial showing that tucatinib added to trastuzumab and pertuzumab maintenance therapy improved outcomes across multiple clinically relevant subgroups of patients with...
Erika Hamilton, MD, discusses...
06/26/2026
Oncology
Bjørn Henning Grønberg, MD, PhD
Videos
Concurrent Radiotherapy, Chemotherapy, and Durvalumab Does Not Improve Outcomes in Extensive-Stage Small Cell Lung Cancer
06/26/2026
Bjørn Henning Grønberg, MD, PhD
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD, discusses results from a phase 3 randomized trial evaluating the addition of concurrent thoracic radiotherapy to platinum/etoposide chemotherapy plus durvalumab in patients with extensive-stage small cell lung...
Bjørn Henning Grønberg, MD, PhD,...
06/26/2026
Oncology
Peter O’Donnell, MD
Videos
Health-Related Quality of Life Preserved with Neoadjuvant and Adjuvant Enfortumab Vedotin plus Pembrolizumab in Cisplatin-Ineligible Patients with Muscle-Invasive Bladder Cancer
06/26/2026
Peter O'Donnell, MD
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the University of Chicago, discusses health-related quality-of-life (HRQoL) findings from the phase 3 KEYNOTE-905 study evaluating perioperative enfortumab vedotin plus pembrolizumab in patients with muscle-invasive...
Peter O’Donnell, MD, of the...
06/26/2026
Oncology
Sanjay Popat, PhD, FRCP
Videos
Pralsetinib Shows Improved Response in RET Fusion–Positive Advanced or Metastatic Non–Small Cell Lung Cancer
06/25/2026
Sanjay Popat, PhD, FRCP
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical oncologist at The Royal Marsden Hospital in London, England, discusses results from the phase 3 AcceleRET-Lung trial evaluating first-line pralsetinib versus standard-of-care histology-specific chemotherapy...
Sanjay Popat, PhD, FRCP, medical...
06/25/2026
Oncology
Walter Weber, MD
Videos
Prepectoral Implant Placement Improves Long-Term Quality of Life After Breast Reconstruction
06/24/2026
Walter Weber, MD
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses results from the phase 3 PREPEC trial showing that prepectoral implant-based breast reconstruction significantly improved long-term quality of life and physical well-being compared with subpectoral reconstruction...
Walter Weber, MD, discusses...
06/24/2026
Oncology
Timothy Cloughesy, MD
Videos
Vorasidenib Maintains Durable Clinical Benefit With Consistent Safety in IDH-Mutated Glioma
06/24/2026
Timothy Cloughesy, MD
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses updated results from the INDIGO trial showing durable disease control, prolonged progression-free survival, and sustained safety with vorasidenib in patients with IDH-mutant grade 2 gliomas.
Timothy Cloughesy, MD, discusses...
06/24/2026
Oncology
Peter Schmid, MD, PhD
Videos
Giredestrant Improves Outcomes Regardless of Menopausal Status in Early Breast Cancer
06/24/2026
Peter Schmid, MD, PhD
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses subgroup analysis results from the lidERA trial showing that giredestrant improved invasive disease-free and distant recurrence-free survival across premenopausal and postmenopausal patients with ER-positive,...
Peter Schmid, MD, PhD, discusses...
06/24/2026
Oncology

Insights From the ESMO Congress

News
NETSARC+ Study Identifies Tumor Location and Size as Prognostic Factors in Patients With Desmoid Tumors
10/28/2026
Emily Estrada
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+...
10/28/2026
Oncology
News
Reduced-Frequency Immunotherapy Fails to Demonstrate Noninferiority in Advanced Cancer in Phase 3 MOIO Trial
10/26/2026
Emily Estrada
Results from the phase 3 MOIO trial demonstrated that reduced-frequency immune checkpoint inhibitor treatment failed to establish progression-free survival noninferiority compared with standard dosing in patients with responding advanced or...
Results from the phase 3 MOIO trial demonstrated that reduced-frequency immune checkpoint inhibitor treatment failed to establish progression-free survival noninferiority compared with standard dosing in patients with responding advanced or...
Results from the phase 3 MOIO...
10/26/2026
Oncology
News
Risvutatug Rezetecan Reduces Progression Risk by 67% in Previously Treated Relapsed or Refractory Osteosarcoma
10/26/2026
Emily Estrada
Results from the phase 3 ARTEMIS-011 trial showed that risvutatug rezetecan significantly prolonged progression-free survival compared with gemcitabine plus docetaxel in heavily pretreated patients with relapsed or refractory osteosarcoma,...
Results from the phase 3 ARTEMIS-011 trial showed that risvutatug rezetecan significantly prolonged progression-free survival compared with gemcitabine plus docetaxel in heavily pretreated patients with relapsed or refractory osteosarcoma,...
Results from the phase 3...
10/26/2026
Oncology
News
Sacituzumab Tirumotecan Outperforms Chemotherapy in Advanced or Recurrent Endometrial Cancer
10/26/2026
Stephanie Holland
Results from the phase 3 TroFuse-005 trial demonstrated significant improvements in survival and response with sacituzumab tirumotecan compared with physician's choice chemotherapy in previously treated advanced or recurrent endometrial...
Results from the phase 3 TroFuse-005 trial demonstrated significant improvements in survival and response with sacituzumab tirumotecan compared with physician's choice chemotherapy in previously treated advanced or recurrent endometrial...
Results from the phase 3...
10/26/2026
Oncology
Brian Slomovitz, MD
Videos
KEYNOTE-C93 Demonstrates Superior PFS With Pembrolizumab Monotherapy in dMMR Endometrial Cancer
10/26/2026
Brian M. Slomovitz, MD
Brian Slomovitz, MD, discusses results from the phase 3 KEYNOTE-C93 trial evaluating first-line pembrolizumab monotherapy versus carboplatin plus paclitaxel in advanced or recurrent mismatch repair–deficient endometrial cancer, highlighting...
Brian Slomovitz, MD, discusses results from the phase 3 KEYNOTE-C93 trial evaluating first-line pembrolizumab monotherapy versus carboplatin plus paclitaxel in advanced or recurrent mismatch repair–deficient endometrial cancer, highlighting...
Brian Slomovitz, MD, discusses...
10/26/2026
Oncology
News
Phase 3 Trial Demonstrates Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Biliary Tract Cancer
10/25/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that ivonescimab plus gemcitabine and cisplatin significantly improved survival and response compared with durvalumab plus chemotherapy in advanced biliary tract cancer, supporting the PD-1/VEGF...
Results from a phase 3 trial demonstrated that ivonescimab plus gemcitabine and cisplatin significantly improved survival and response compared with durvalumab plus chemotherapy in advanced biliary tract cancer, supporting the PD-1/VEGF...
Results from a phase 3 trial...
10/25/2026
Oncology
News
Sonesitatug Vedotin Significantly Improves Overall Survival in CLDN18.2-Positive Advanced Gastroesophageal Cancer
10/25/2026
Stephanie Holland
Results from the phase 3 CLARITY-Gastric 01 trial demonstrated significant overall survival benefits with sonesitatug vedotin in previously treated CLDN18.2-positive advanced gastroesophageal cancer, supporting the antibody-drug conjugate as...
Results from the phase 3 CLARITY-Gastric 01 trial demonstrated significant overall survival benefits with sonesitatug vedotin in previously treated CLDN18.2-positive advanced gastroesophageal cancer, supporting the antibody-drug conjugate as...
Results from the phase 3...
10/25/2026
Oncology
News
Osimertinib Plus Savolitinib Outperforms Chemotherapy in EGFR-Mutated, MET-Altered Advanced NSCLC Following Osimertinib
10/25/2026
Stephanie Holland
Results from the phase 3 SAFFRON trial demonstrated that osimertinib plus savolitinib significantly improved survival compared with platinum-based chemotherapy in patients with EGFR-mutated, MET-altered advanced non-small cell lung cancer...
Results from the phase 3 SAFFRON trial demonstrated that osimertinib plus savolitinib significantly improved survival compared with platinum-based chemotherapy in patients with EGFR-mutated, MET-altered advanced non-small cell lung cancer...
Results from the phase 3 SAFFRON...
10/25/2026
Oncology
Ferdinandos Skoulidis, MD, PhD
Videos
KRAScendo-1: Divarasib Significantly Improves Survival Over Sotorasib or Adagrasib in KRAS G12C-Mutated Non-Small Cell Lung Cancer
10/25/2026
Ferdinandos Skoulidis, MD, PhD
Ferdinandos Skoulidis, MD, PhD, discusses results from the phase 3 KRAScendo-1 trial demonstrating that divarasib significantly improved survival and response compared with sotorasib or adagrasib in previously treated patients with locally...
Ferdinandos Skoulidis, MD, PhD, discusses results from the phase 3 KRAScendo-1 trial demonstrating that divarasib significantly improved survival and response compared with sotorasib or adagrasib in previously treated patients with locally...
Ferdinandos Skoulidis, MD, PhD,...
10/25/2026
Oncology
News
Longer Follow-Up From HERIZON-GEA-01 Reinforces Survival Benefit of Zanidatamab-Based Regimens
10/25/2026
Stephanie Holland
Updated results from the phase 3 HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy significantly improved overall survival compared with trastuzumab plus chemotherapy in previously untreated patients with HER2-positive...
Updated results from the phase 3 HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy significantly improved overall survival compared with trastuzumab plus chemotherapy in previously untreated patients with HER2-positive...
Updated results from the phase 3...
10/25/2026
Oncology

Live Meetings

Recent News

News
Real-World Study Demonstrates Clinical Activity of Lurbinectedin in Previously Treated Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz EMERGE 402 study demonstrated clinically meaningful antitumor activity with lurbinectedin in previously treated small cell lung cancer, with lower response rates among patients with baseline central nervous...
Results from the phase 4 Jazz...
10/28/2026
Oncology
News
NETSARC+ Study Identifies Tumor Location and Size as Prognostic Factors in Patients With Desmoid Tumors
10/28/2026
Emily Estrada
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+ registry analysis demonstrated a substantial decline in surgical management of desmoid tumors over time and identified tumor size and anatomical location as prognostic factors for progression-free survival,...
Results from a large NETSARC+...
10/28/2026
Oncology
News
G-CSF Prophylaxis Reduces Incidence of Febrile Neutropenia Without Compromising Chemoimmunotherapy Outcomes in Patients With Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter, retrospective trial demonstrated that granulocyte colony-stimulating factor prophylaxis was associated with significantly reduced febrile neutropenia rates and fewer related acute-care visits in patients with small...
Results from a multicenter,...
10/28/2026
Oncology
News
Tambotatug Pelitecan Significantly Improves Overall Survival in Patients With Relapsed Small Cell Lung Cancer
10/28/2026
Emily Estrada
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3 TAISHAN-302 trial demonstrated that tambotatug pelitecan significantly improved overall survival, progression-free survival, and objective response compared with topotecan in patients with relapsed small cell lung...
Results from the phase 3...
10/28/2026
Oncology
News
Oral Hypomethylating Agents Show Comparable Hematologic Toxicity to Intravenous Therapy in Patients With Myelodysplastic Syndromes and Acute Myeloid Leukemia
10/28/2026
Emily Estrada
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter retrospective study found that no statistically significant differences in hematologic toxicity between oral and intravenous hypomethylating agents in patients with myelodysplastic syndromes or acute myeloid...
Results from a multicenter...
10/28/2026
Oncology
News
Phase 3 Results Support Regulatory Submission of Oral Azacitidine Plus Cedazuridine in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
10/28/2026
Emily Estrada
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND trial demonstrated that oral azacitidine plus cedazuridine met its primary pharmacokinetic exposure end point compared with subcutaneous azacitidine in patients with myelodysplastic syndromes or chronic...
Results from the phase 3 AZTOUND...
10/28/2026
Oncology
News
Varegacestat Demonstrates Promising Antitumor Activity in Patients With Progressive Desmoid Tumors
10/28/2026
Emily Estrada
Results from the phase 2 RINGSIDE trial demonstrated sustained antitumor activity with varegacestat in patients with progressive desmoid tumors, with once daily dosing producing greater tumor volume reductions and higher response rates than...
Results from the phase 2 RINGSIDE trial demonstrated sustained antitumor activity with varegacestat in patients with progressive desmoid tumors, with once daily dosing producing greater tumor volume reductions and higher response rates than...
Results from the phase 2...
10/28/2026
Oncology
FDA Approval
FDA Expands Talazoparib Plus Enzalutamide Indication to HRR-Mutated Metastatic Prostate Cancer
10/26/2026
Emily Estrada
Based on results from the phase 3 TALAPRO-3 trial, the FDA has approved talazoparib plus enzalutamide for patients with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, following a significant...
Based on results from the phase 3 TALAPRO-3 trial, the FDA has approved talazoparib plus enzalutamide for patients with HRR-mutated metastatic androgen pathway modulation-naïve or -sensitive prostate cancer, following a significant...
Based on results from the phase...
10/26/2026
Oncology
News
Reduced-Frequency Immunotherapy Fails to Demonstrate Noninferiority in Advanced Cancer in Phase 3 MOIO Trial
10/26/2026
Emily Estrada
Results from the phase 3 MOIO trial demonstrated that reduced-frequency immune checkpoint inhibitor treatment failed to establish progression-free survival noninferiority compared with standard dosing in patients with responding advanced or...
Results from the phase 3 MOIO trial demonstrated that reduced-frequency immune checkpoint inhibitor treatment failed to establish progression-free survival noninferiority compared with standard dosing in patients with responding advanced or...
Results from the phase 3 MOIO...
10/26/2026
Oncology
News
Risvutatug Rezetecan Reduces Progression Risk by 67% in Previously Treated Relapsed or Refractory Osteosarcoma
10/26/2026
Emily Estrada
Results from the phase 3 ARTEMIS-011 trial showed that risvutatug rezetecan significantly prolonged progression-free survival compared with gemcitabine plus docetaxel in heavily pretreated patients with relapsed or refractory osteosarcoma,...
Results from the phase 3 ARTEMIS-011 trial showed that risvutatug rezetecan significantly prolonged progression-free survival compared with gemcitabine plus docetaxel in heavily pretreated patients with relapsed or refractory osteosarcoma,...
Results from the phase 3...
10/26/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use